The efficacy of early treatment with convalescent plasma in patients with COVID-19 is debated. Nothing is known about the potential effect of other plasma components other than anti-SARS-CoV-2 antibodies.
Convalescent or standard plasma versus standard of care in the treatment of COVID-19 patients with respiratory impairment: short and long-term effects. A three-arm randomized controlled clinical trial
Ciccone, Giovannino;De Rosa, Francesco Giuseppe;Cavallo, Rossana;Castiglione, Anna;Birocco, Nadia;Hu, Huijing;Pecoraro, Clara;Guaschino, Roberto;Avolio, Maria;Costa, Cristina;Raso, Samuele;Baffa, Alessandra;Russo, Alessandra;Maddalena, Laura;Marletto, Fabio Paolo;Baldassano, Stefano;Canta, Francesca;Bergamo, Daniele;Vitale, Francesco;Liccardi, Marco Maria;Calcagno, Andrea;Libanore, Valentina;Blangetti, Ilaria;Benedetti, Valentina;Mitola, Barbara;Scozzari, Gitana;Brazzi l
2022-01-01
Abstract
The efficacy of early treatment with convalescent plasma in patients with COVID-19 is debated. Nothing is known about the potential effect of other plasma components other than anti-SARS-CoV-2 antibodies.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
222 - Convalescent - Manzini.pdf
Accesso riservato
Tipo di file:
PDF EDITORIALE
Dimensione
997.75 kB
Formato
Adobe PDF
|
997.75 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
